Abstract
Kidney disease affects around 40% of people with type 2 diabetes and is a leading cause of morbidity and mortality.1 Management of diabetic kidney disease has traditionally focused on tight glycaemic control (in the early stages) and blood pressure control (with agents that inhibit the renin–angiotensin system).1 Despite this, most patients with diabetic kidney disease experience a gradual decline in kidney function, eventually progressing to end-stage kidney disease and an increased risk of cardiovascular events and mortality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
